Phenotypic Characterization of Juvenile Idiopathic Arthritis in African American Children

Stevens, Kelly R.; Fitzpatrick, Lauren; Broadaway, K. Alaine; Ponder, Lori; Angeles‐Han, Sheila T.; Jenkins, Kirsten; Rouster‐Stevens, Kelly; Pelajo, Christina F.; Conneely, Karen N.; Epstein, Michael P.; Lopez-Benitez, Jorge M.; Vogler, Larry B.; Prahalad, Sampath

doi:10.3899/jrheum.150891

Cited by 17 publications

(18 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of 14-3-3η positivity in children with PJIA RF + was similar to that in another study on early undifferentiated polyarthritis in adults. However, in both early and established RA, a higher prevalence of 14-3-3η (68%) was reported compared to our pediatric population [17,18]. In a previous report, 14-3-3η was positive in 21% of patients with early RA who were seronegative for RF and CCP antibodies, and in 67% of patients with seronegative established RA and in a pediatric study, 31% of PJIA RF-patients had positive 14-3-3η levels [15,19].…”

Section: Discussioncontrasting

confidence: 75%

See 1 more Smart Citation

Prevalence and Significance of Serum 14-3-3η(eta) in Juvenile Idiopathic Arthritis

Reyhan

Zhukov

Lagier

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Prompt diagnosis of juvenile idiopathic arthritis (JIA) is important to avoid long term complications. Elevated serum 14-3-3η levels improve the diagnostic sensitivity of rheumatoid factor (RF) and cyclic citrullinated peptide (CCP) antibody in adult rheumatoid arthritis (RA), and have been associated with more severe phenotype. We investigated the prevalence and clinical significance of serum 14-3-3η in different types of JIA.Methods JIA patients (n = 152) followed by the Pediatric Rheumatology Core at Children’s Hospital of Los Angeles were categorized into 5 groups: polyarticular JIA RF+ (PJIA RF+; n = 39), PJIA RF- (n = 39), psoriatic arthritis (PsA; n = 20), enthesitis-related arthritis (ERA; n = 18), and oligoarticular JIA (OJIA [control group]; n = 36). RF, CCP antibody, and 14-3-3η were measured for all patients. 14-3-3η serum levels ≥ 0.2 ng/mL were considered positive. Disease activity was assessed by the Juvenile Arthritis Disease Activity Score-71 (JADAS-71).Results Elevated 14-3-3η levels were detected in 35/152 (23%) patients, and across all groups tested. Most patients with 14-3-3η had titers ≥ 4 times above the cutoff value. The majority (23, 67%) of 14-3-3η-positive patients were also positive for RF or CCP antibodies, 17 (49%) were positive for all 3, and 12 (8%) were single-positive for 14-3-3η. The highest prevalence of 14-3-3η was in PJIA RF + patients (49%), followed by OJIA (22%). Positivity for 14-3-3η was not significantly associated with disease activity or age at diagnosis.Conclusion Serum 14-3-3η can be detected in all forms of JIA tested but appears to be most common in PJIA RF+. 14-3-3η does not appear to correlate with disease activity in JIA.

show abstract

Section: Discussioncontrasting

confidence: 75%

“…Overall in our study, the prevalence of JIA was much higher among female patients (78%), compared to previous reports of a 2 to 1 female to male ratio, respectively [1, 5,17]. PJIA RF + mimics adult RA and, as expected, the PJIA RF + population had the highest prevalence of being positive for 14-3-3η (49%).…”

Section: Discussionsupporting

confidence: 49%

Prevalence and Significance of Serum 14-3-3η(eta) in Juvenile Idiopathic Arthritis

Reyhan

Zhukov

Lagier

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…The prevalence of 14-3-3h positivity in children with PJIA RF+ was similar to that in another study on early undifferentiated polyarthritis in adults. However, in both early and established RA, a higher prevalence of 14-3-3h (68%) was reported compared to our pediatric population [21,22]. In a previous report, 14-3-3h was positive in 21% of patients with early RA who were seronegative for RF and CCP antibodies, and in 67% of patients with seronegative established RA and in a pediatric study, 31% of PJIA RF-patients had positive 14-3-3h levels [16,23].…”

Section: Discussioncontrasting

confidence: 74%

“…To date this is the largest published pediatric study assessing the importance of 14-3-3h in children with JIA. Overall, in our study, the prevalence of JIA was much higher among female patients (78%), compared to previous reports of a 2 to 1 female to male ratio, respectively [1,6,21]. PJIA RF+ mimics adult RA and, as expected, the PJIA RF+ population had the highest prevalence of 14-3-3h positivity (49%).…”

Section: Discussionsupporting

confidence: 50%

Prevalence and Significance of Serum 14-3-3η in Juvenile Idiopathic Arthritis

Reyhan¹,

Zhukov²,

Lagier³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Prompt diagnosis of juvenile idiopathic arthritis (JIA) is important to avoid long term complications. Elevated serum 14-3-3η levels improve the diagnostic sensitivity of rheumatoid factor (RF) and cyclic citrullinated peptide (CCP) antibody in adult rheumatoid arthritis (RA), and have been associated with more severe phenotype. We investigated the prevalence and clinical significance of serum 14-3-3η in different types of JIA.Methods: JIA patients (n=151) followed by the Pediatric Rheumatology Core at Children’s Hospital of Los Angeles were categorized into 5 groups: polyarticular JIA RF+ (PJIA RF+; n=39), PJIA RF- (n=39), psoriatic arthritis (PsA; n=19), enthesitis-related arthritis (ERA; n=18), and oligoarticular JIA (OJIA [control group]; n=36). RF, CCP antibody, and 14-3-3η were measured for all patients. 14-3-3η serum levels >0.2ng/mL were considered positive. Disease activity was assessed by the Juvenile Arthritis Disease Activity Score-71 (JADAS-71). Results: Elevated 14-3-3h levels were detected in 34/151 (23%) patients, and across all groups tested. Most patients with 14-3-3h had titers ≥4 times above the cutoff value. The majority (22, 65%) of 14-3-3h-positive patients were also positive for RF or CCP antibodies, 16 (47%) were positive for all 3, and 12 (35%) were single-positive for 14-3-3η. The highest prevalence of 14-3-3η was in PJIA RF+ patients (49%), followed by OJIA (22%). Positivity for 14-3-3h was not significantly associated with disease activity or age at diagnosis. Conclusion: Serum 14-3-3h can be detected in all forms of JIA tested but appears to be most common in PJIA RF+. 14-3-3h does not appear to correlate with disease activity in JIA.

show abstract

“…The first version of this observational registry was funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) American Recovery and Reinvestment Act Grand Opportunities grant RC2AR058934 in 2009 and enrolled 9,500 patients over 3 years at 62 CARRA sites. The Legacy Registry demonstrated the feasibility of capturing data from a large cohort of children with a range of rheumatic diseases, and the resulting data have been used to describe phenotypes, treatment patterns, and disease outcomes for a number of pediatric rheumatic diseases (6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20).…”

Section: Carra and The Carra Registrymentioning

confidence: 99%

The Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans

Ringold

Nigrović

Feldman

et al. 2018

Arthritis & Rheumatology

View full text Add to dashboard Cite

The pediatric rheumatic diseases are a heterogeneous group of rare diseases, posing a number of challenges for the use of traditional clinical and translational research methods. Innovative comparative effectiveness approaches are needed to efficiently study treatment strategies and disease outcomes. The Childhood Arthritis and Rheumatology Research Alliance (CARRA) developed the consensus treatment plan (CTP) approach as a comparative effectiveness tool for research in pediatric rheumatology. CTPs are treatment strategies, developed by consensus methods among CARRA members, intended to reduce variation in treatment approaches, standardize outcome measurements, and allow for comparison of the effectiveness of different approaches with the goal of improving disease outcomes. To date, CTPs have been published for 8 different diseases and disease manifestations. The approach has been successfully piloted for juvenile localized scleroderma, systemic juvenile idiopathic arthritis (JIA), polyarticular JIA, dermatomyositis, and lupus nephritis. Large-scale studies are underway for systemic JIA and polyarticular JIA, with the CARRA patient registry serving as the data collection platform. These studies have been designed with stakeholder involvement, including active input from CARRA providers, patients, and parents, with the goal of increasing feasibility and ensuring the relevance of the outcomes. These studies include ancillary biologic specimen collection intended to support additional translational and mechanistic studies. Data from these ongoing CTP studies will provide more information on the ability of this approach to identify effective treatment strategies and improve outcomes in the pediatric rheumatic diseases.

show abstract

Phenotypic Characterization of Juvenile Idiopathic Arthritis in African American Children

Cited by 17 publications

References 15 publications

Prevalence and Significance of Serum 14-3-3η(eta) in Juvenile Idiopathic Arthritis

Prevalence and Significance of Serum 14-3-3η(eta) in Juvenile Idiopathic Arthritis

Prevalence and Significance of Serum 14-3-3η in Juvenile Idiopathic Arthritis

The Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans

Contact Info

Product

Resources

About